Success examples
Enhancing delivery of poorly water-soluble drugs by innovative amorphous solid dispersions

Jermain S. V.

The University of Texas at Austin 2019.

CCR1 antagonist
DOI
Success examples
The inhibitory effect of common food spices bioactive compounds against KRAS G12C and KRAS G12D: an in-silico approach

Agosile O. O., Njoku P. C., Oduwe U., Aremu A. J., Fajobi S. J., Akachukwu S. O., Adebisi A. R., Abolaji A. O., Omirin E. S.

Research Square 2023, PREPRINT (Version 1).

KRAS switch I/II pocket inhibitor
DOI
Success examples
Novel GLP-1 secretagogues as neuroprotective agents for retinal neurodegenerative diseases

Powell F. L., Thomas S., Martin P. M.

Invest. Ophthalmol. Vis. Sci. 2023, 64(8):1842.

GPR142 Agonist
DOI
Success examples
A cathepsin C-like protease mediates the post-translation modification of Toxoplasma gondii secretory proteins for optimal invasion and egress

Thornton L. B., Key M., Micchelli C., Stasic A. J., Kwain S., Floyd K., Moreno S. N. J., Dominy B. N., Whitehead D. C., Dou Z.

mBio 2023, e0017423. Epub 2023 Jun 16.

DPAP1 Inhibitor
DOI
PubMed
Success examples
Canonical BAF complex activity shapes the enhancer landscape that licenses CD8+ T cell effector and memory fates

McDonald B., Chick B. Y., Ahmed N. S., Burns M., Ma S., Casillas E., Chen D., Mann T. H., O'Connor C., Hah N., Hargreaves D. C., Kaech S. M.

Immunity 2023, 56(6):1303-1319.e5.

SMARCA2/4 PROTAC
DOI
PubMed